TrialA Phase 2 Study to Evaluate the Safety, Tolerability, PK and PD in Cystic Fibrosis Patients With at Least 1 G542X Allele
Trial details
- Registry ID
- NCT04126473
- Phase
- Phase 2
Drug research
ELX-02
Open a linked trial to see its study details and recorded changes, or check the regulatory events below and follow their sources.
Drug identity checked against registry records
A drug appearing in a clinical trial does not mean it is FDA-approved. Check the original regulatory source for any approval claim.
Included trials
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| A Phase 2 Study to Evaluate the Safety, Tolerability, PK and PD in Cystic Fibrosis Patients With at Least 1 G542X AlleleNCT04126473 | ELOX | Phase 2 | Completed | 2022-04-06Actual |
| A Study of ELX-02 in Patients With Alport SyndromeNCT05448755 | ELOX | Phase 2 | Completed | 2023-09-11Actual |
A Study of ELX-02 in Patients With Alport Syndrome
Trial details
- Registry ID
- NCT05448755
- Phase
- Phase 2
Regulatory dates and decisions
| No regulatory events match this view.Try another date range or view. Events appear after automated source checks. This does not mean no FDA events have occurred. Dates that a source does not disclose stay undisclosed. |